Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.632%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Announces Strengthening Sales

24 Oct 2011 07:00

RNS Number : 6687Q
Angle PLC
24 October 2011
 



For immediate release

24 October 2011

 

ANGLE plc

 

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES STRENGTHENING SALES

 

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, which specialises in computer games middleware, has made significant progress on a number of fronts.

 

Sales continue to grow at an encouraging rate. Geomerics' Enlighten technology is now being employed in 18 titles worldwide and is currently in evaluation and under consideration for many more. Among these titles are two of the most hotly anticipated games of 2011. Battlefield 3, from EA DICE, is released on 28th October. It is considered a challenger to Call of Duty's market dominance. The game has been backed by a $100m marketing campaign and has received high praise and multiple awards for the quality of its graphics, of which the lighting is driven by Geomerics' Enlighten engine. Battlefield 3 is followed by the release of Need for Speed: The Run on 18th November. This is the next game in one of the most successful franchises of all time and is built on the same Enlighten technology as Battlefield 3.

 

Geomerics is also delighted that it has secured its first deal inside Korea, which will see Enlighten used in multiple titles. This opens up a whole new market for Enlighten and, on the back of sales in Japan, demonstrates that Geomerics is on its way to establishing a strong base in the Asian market.

 

Geomerics' participation in Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme continues to go well and is yielding a range of new sales opportunities.

 

Finally, Geomerics has been awarded new grant funding to research applications of its technology on mobile devices. Geomerics will receive €470,000 over the next three years as part of a €2.8 million EU-funded project researching the next generation of graphics technology for mobile platforms.

 

 

 

Chris Doran, Founder of Geomerics, commented:

"At Geomerics we have tracked the rise in performance of mobile platforms very closely. It is clear that they are fast approaching console performance, and at the high end will overtake this in 2012. We are very excited about the prospect of taking our console technology to mobile platforms, and to contributing to joint R&D on the future direction of graphics technology for mobile devices."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are very pleased with the Geomerics' continued strong progress and look forward to the positive market impact when Battlefield 3 launches at the end of this week."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 

About Geomerics www.geomerics.com

 

Geomerics is an innovation-led company developing cutting-edge graphics technology for the games industry. Based in Cambridge, UK, Geomerics has built a team that combines world-class management and games industry experience with some of the UK's leading researchers. Geomerics launched its groundbreaking Enlighten technology in 2009. Enlighten redefines how designers use and control lighting within a game.

 

Geomerics partners with many of the leading companies in the games industry and is currently working with developers around the world on AAA titles for release in 2011 and 2012. The first titles incorporating Enlighten include the highly anticipated 'Battlefield 3' and 'Need for Speed: The Run'.

 

For more details about Geomerics research into mobile platforms, visit www.lpgpu.org 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDGLBDBGBX
Date   Source Headline
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.